A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas
Status:
Unknown status
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
Low grade gliomas (LGGs) are the most common primary central nervous system malignancies.
Brain surgeries with the most possible extent of resection are endeavored to achieve longer
survivals in LGG patients. For patients with tumor located in eloquent areas so that gross
total resection is not applicable, National Comprehensive Cancer Network (NCCN) 2013
guidelines assigned both radiotherapy or chemotherapy as adjuvant treatments of low grade
glioma following surgeries. Retrospective studies have suggested that temozolomide (an oral
chemotherapeutics) chemotherapy have good effects on the control of tumor progression or
recurrence in LGG patients after surgeries, especially in those with isocitrate dehydrogenase
(IDH) gene mutations.
Therefore, our prospective cohort study is to provide a higher level(IIb) of evidence for the
correlation between IDH mutation and the responsiveness to up-front adjuvant metronomic
temozolomide chemotherapy in young patients with LGG located in eloquent brain areas. And
hopefully justify future RCTs with comparison between effects of adjuvant radiotherapy and
chemotherapy in these patients.